The investigative HIV integrase inhibitor raltegravir effectively reduces virus to undetectable levels even when the virus is resistant to three classes of antiretrovirals.
In the 48-week analysis, doctors said that more than half of all patients on one of three different dosages of raltegravir achieved an undetectable viral load.
In a report to the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), researchers said that all doses of raltegravir were superior to an optimized background of available antiretrovirals.
read more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment